Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS‐AKI
Eva Maria Schleicher, Christian Labenz, Frank Erhard Uschner, Julian Pohl, Moritz Passenberg, Michael Praktiknjo, Marcus Maximilian Mücke, Henrik Karbannek, Nina Böhling, Karsten Große, Marlene Reincke, Sarah Schütte · 2026
Read Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS‐AKI by Eva Maria Schleicher, Christian Labenz, Frank Erhard Uschner, Julian Pohl, Moritz Passenberg, Michael Praktiknjo, Marcus Maximilian Mücke, Henrik Karbannek, Nina Böhling, Karsten Große, Marlene Reincke, Sarah Schütte (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13625807.txt.
Description
Eva Maria Schleicher and colleagues, with the German cirrhosis study group, ask how long doctors should give albumin before starting a key drug for a failing liver-kidney syndrome. Albumin infusions help confirm hepatorenal syndrome, yet waiting delays terlipressin, the drug that can reverse it. Twelve German centers contributed 145 patients, split by whether albumin ran under a day or one to two and a half days before the drug began.
About four in ten patients responded fully to treatment, and the response rate matched between the two timing groups. Longer albumin time also failed to change the odds of avoiding dialysis and transplant or of surviving. Shorter workups, the authors conclude, do not seem to cost patients their chance of response, which may speed treatment where beds and albumin are scarce.
Catalog record
| CREATOR | Eva Maria Schleicher, Christian Labenz, Frank Erhard Uschner, Julian Pohl, Moritz Passenberg, Michael Praktiknjo, Marcus Maximilian Mücke, Henrik Karbannek, Nina Böhling, Karsten Große, Marlene Reincke, Sarah Schütte |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |